Quick Answer
Lilly's GLP-1 pill orforglipron beat oral semaglutide in a Phase 3 trial, delivering far greater weight loss with no food or water restrictions. A needle-free option may reach India soon.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
For millions of Indians who want the benefits of GLP-1 medications like Ozempic and Mounjaro but cannot imagine injecting themselves every week, the news from June 9, 2026 matters. Eli Lilly announced that its once-daily GLP-1 pill, orforglipron, beat oral semaglutide head-to-head in a large Phase 3 trial of type 2 diabetes patients — producing better blood sugar control and substantially more weight loss, with a safety profile similar to the injectable GLP-1 drugs already used worldwide. The era of effective, needle-free GLP-1 treatment is no longer a prediction. It has arrived, and it is likely to reach India sooner than many expect.
What Happened
Lilly reported results from a Phase 3 trial that directly compared orforglipron against oral semaglutide — the pill version of Ozempic sold as Rybelsus — in adults with type 2 diabetes. According to the company, orforglipron delivered a 73.6 percent greater relative reduction in body weight at the highest-dose comparison, along with stronger improvements in blood sugar control. Side effects were mainly the familiar GLP-1 ones: nausea, vomiting, and constipation, mostly mild to moderate and concentrated during dose increases. The announcement was covered by Indian outlets including Business Standard, reflecting how closely India is watching this drug.
This follows another milestone earlier in 2026. In April, the US FDA approved orforglipron — sold in America under the brand name Foundayo — as the first GLP-1 pill for weight loss that can be taken at any time of day, with no food or water restrictions.
Why a Pill Is Such a Big Deal
Current GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are peptide medicines. They must be injected weekly, stored in a refrigerator, and shipped through an unbroken cold chain. Oral semaglutide exists, but it is a fragile molecule — it must be taken on an empty stomach with only a sip of water, and the patient must then wait 30 minutes before eating or drinking anything. Many patients find this routine hard to sustain.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
Orforglipron is different. It is a small-molecule drug, not a peptide. That means three practical advantages. First, it is a simple once-daily tablet with no food or water restrictions. Second, it needs no refrigeration or cold chain — a major advantage in a country like India where summer temperatures and long supply routes complicate injectable distribution. Third, small molecules are significantly cheaper to manufacture at scale than peptide injections, which is exactly what is needed for prices that work in the Indian market.
What This Means for Indian Patients
India has over 100 million people with type 2 diabetes and rapidly rising obesity, yet GLP-1 adoption has been held back by two barriers: needle hesitancy and cost. A once-daily pill addresses the first directly. Many patients who refused injectable therapy outright will consider a tablet.
On cost, the timing is favourable. The semaglutide patent expired in India in March 2026, and generic semaglutide from Indian manufacturers now starts at a fraction of the original branded price. When orforglipron launches in India, it will enter a fiercely competitive market — which historically pushes global drugmakers to price aggressively here. Lilly already sells Mounjaro in India and has stated its intention to launch orforglipron globally. While no Indian approval date has been announced yet, CDSCO review typically follows major FDA approvals within one to two years, and Lilly has been notably fast in bringing its newer drugs to India.
What Should You Do Now
If you are already on a GLP-1 injection and doing well, there is no reason to stop or wait — switching decisions should only be made with your doctor once orforglipron is actually available and priced in India. If you have been delaying GLP-1 treatment because of needle fear, do not put your health on hold for a future launch. Oral semaglutide is already available in India today, generic injectable semaglutide is now highly affordable, and a specialist can match you to the option that fits your body, your budget, and your comfort level — then help you transition to newer pills as they arrive.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The bottom line: GLP-1 therapy is becoming easier, cheaper, and needle-free. The best step an Indian patient can take today is a proper medical assessment, so you are ready to benefit from these options safely.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. Business Standard — https://www.business-standard.com/health/lilly-claims-oral-glp-1-pill-beat-oral-semaglutide-in-diabetes-trials-126060901020_1.html 2. Eli Lilly — https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically 3. Eli Lilly — https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.